Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Ramucirumab (genetical recombination)

August 30, 2022

Therapeutic category

Other antitumor agents

Non-proprietary name

Ramucirumab (genetical recombination)

Safety measure

Precautions should be revised.

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Thrombotic microangiopathy</u> <u>If anaemia accompanied by schizocytes, thrombocytopenia, renal impairment, etc. are observed, administration of this drug should be discontinued, and appropriate measures should be taken.</u>

(N/A) Not Applicable. No corresponding language is included in the current Precautions.